European Pharmaceutical Review

DECEMBER 19, 2023

Many of today’s vaccines are produced in ready-to-inject liquid formulations that must be kept cold to maintain stability. However, this greatly complicates both the worldwide distribution and stockpiling of vaccines and other drugs. A requisite cold chain has been designed and implemented to be uninterrupted from factory to patient.

Vaccines 111

Vaccines Communication Immunization Documentation 111

European Pharmaceutical Review

FEBRUARY 27, 2024

In 2012, Dame June was elected as the first chair of the European Pharmacovigilance Risk Assessment Committee, MHRA added. MHRA also noted that Dame June’s key interests are in monitoring the outcomes of regulatory action, risk communication and patient involvement in the regulatory process.

Communication 111

Communication Vaccines 111

ISPE

AUGUST 30, 2022

During the pandemic, the pharmaceutical industry faced challenges in the production of COVID-19 therapeutics and vaccines to meet global demand, as well as mitigation of drug shortages for non-COVID-19-related products, without compromising product quality or patient safety. Published May 2012. Published 2008.

Documentation 52

Documentation FDA Packaging Communication 52

Pharmaceutical Technology

JANUARY 25, 2023

7,000 more clinical trials take place each year in the Asia-Pacific region compared with 2012, and 1,200 more in the Middle East and Africa. The global vaccine rollout would never have taken place without the advances in visibility and control over supply chains that it necessitated. The world of clinical trials is changing.

Vaccines 59

Vaccines Pharmaceutical Companies Pharmaceutical Companies Communication 59

Pharmaceutical Technology

JANUARY 25, 2023

7,000 more clinical trials take place each year in the Asia-Pacific region compared with 2012, and 1,200 more in the Middle East and Africa. The global vaccine rollout would never have taken place without the advances in visibility and control over supply chains that it necessitated. The world of clinical trials is changing.

Vaccines 52

Vaccines Pharmaceutical Companies Pharmaceutical Companies Communication 52

pharmaphorum

FEBRUARY 26, 2021

In 2012, J&J agreed to pay US $181 million to 26 states in order to settle these claims – though another lawsuit related to the drug (for $8 billion, eventually reduced to $6.8 CEO Alex Gorsky, who was appointed in 2012. Risperdal is well-known due to the controversy in the US following its product launch in 1994.

Vaccines 126

Vaccines Communication Labelling 126

ISPE

MARCH 8, 2023

2 , 16 , 17 , 18 One example is the switching of tributyltin azide with sodium azide and dimethyl formamide by Zhejiang Huahai Pharmaceuticals (ZHP) in 2012 to reduce waste and to increase yield in the production of angiotensin II receptor blockers, resulting in the formation of N-nitrosodimethylamine (NDMA), a known carcinogenic impurity.

Compounding 52

Compounding Compounding Pharmacies Packaging FDA 52